FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice

Vivianne Deng, Valerie Matagne, Fatima Banine, Matthew Frerking, Patricia Ohliger, Sarojini Budden, Jonathan Pevsner, Gregory Dissen, Lawrence (Larry) Sherman, Sergio Ojeda

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Rett syndrome (RTT) is an X-linked neurodevelopmental disorder linked to heterozygous de novo mutations in the MECP2 gene. MECP2 encodes methyl-CpG-binding protein 2 (MeCP2), which represses gene transcription by binding to 5-methylcytosine residues in symmetrically positioned CpG dinucleotides. Direct MeCP2 targets underlying RTT pathogenesis remain largely unknown. Here, we report that FXYD1, which encodes a transmembrane modulator of Na+,K+-ATPase activity, is elevated in frontal cortex (FC) neurons of RTT patients and Mecp2-null mice. Increasing neuronal FXDY1 expression is sufficient to reduce dendritic arborization and spine formation, hallmarks of RTT neuropathology. Mecp2-null mouse cortical neurons have diminished Na+,K+-ATPase activity, suggesting that aberrant FXYD1 expression contributes to abnormal neuronal activity in RTT. MeCP2 represses Fxyd1 transcription through direct interactions with sequences in the Fxyd1 promoter that are methylated in FC neurons. FXYD1 is therefore a MeCP2 target gene whose de-repression may directly contribute to RTT neuronal pathogenesis.

Original languageEnglish (US)
Pages (from-to)640-650
Number of pages11
JournalHuman Molecular Genetics
Volume16
Issue number6
DOIs
StatePublished - Mar 15 2007

Fingerprint

Methyl-CpG-Binding Protein 2
Rett Syndrome
Brain
Genes
Frontal Lobe
Neurons
5-Methylcytosine
Dendritic Spines
Neuronal Plasticity
Mutation

ASJC Scopus subject areas

  • Genetics

Cite this

FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. / Deng, Vivianne; Matagne, Valerie; Banine, Fatima; Frerking, Matthew; Ohliger, Patricia; Budden, Sarojini; Pevsner, Jonathan; Dissen, Gregory; Sherman, Lawrence (Larry); Ojeda, Sergio.

In: Human Molecular Genetics, Vol. 16, No. 6, 15.03.2007, p. 640-650.

Research output: Contribution to journalArticle

Deng, Vivianne ; Matagne, Valerie ; Banine, Fatima ; Frerking, Matthew ; Ohliger, Patricia ; Budden, Sarojini ; Pevsner, Jonathan ; Dissen, Gregory ; Sherman, Lawrence (Larry) ; Ojeda, Sergio. / FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. In: Human Molecular Genetics. 2007 ; Vol. 16, No. 6. pp. 640-650.
@article{9ae3688783da46eab99766c7284bd709,
title = "FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice",
abstract = "Rett syndrome (RTT) is an X-linked neurodevelopmental disorder linked to heterozygous de novo mutations in the MECP2 gene. MECP2 encodes methyl-CpG-binding protein 2 (MeCP2), which represses gene transcription by binding to 5-methylcytosine residues in symmetrically positioned CpG dinucleotides. Direct MeCP2 targets underlying RTT pathogenesis remain largely unknown. Here, we report that FXYD1, which encodes a transmembrane modulator of Na+,K+-ATPase activity, is elevated in frontal cortex (FC) neurons of RTT patients and Mecp2-null mice. Increasing neuronal FXDY1 expression is sufficient to reduce dendritic arborization and spine formation, hallmarks of RTT neuropathology. Mecp2-null mouse cortical neurons have diminished Na+,K+-ATPase activity, suggesting that aberrant FXYD1 expression contributes to abnormal neuronal activity in RTT. MeCP2 represses Fxyd1 transcription through direct interactions with sequences in the Fxyd1 promoter that are methylated in FC neurons. FXYD1 is therefore a MeCP2 target gene whose de-repression may directly contribute to RTT neuronal pathogenesis.",
author = "Vivianne Deng and Valerie Matagne and Fatima Banine and Matthew Frerking and Patricia Ohliger and Sarojini Budden and Jonathan Pevsner and Gregory Dissen and Sherman, {Lawrence (Larry)} and Sergio Ojeda",
year = "2007",
month = "3",
day = "15",
doi = "10.1093/hmg/ddm007",
language = "English (US)",
volume = "16",
pages = "640--650",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice

AU - Deng, Vivianne

AU - Matagne, Valerie

AU - Banine, Fatima

AU - Frerking, Matthew

AU - Ohliger, Patricia

AU - Budden, Sarojini

AU - Pevsner, Jonathan

AU - Dissen, Gregory

AU - Sherman, Lawrence (Larry)

AU - Ojeda, Sergio

PY - 2007/3/15

Y1 - 2007/3/15

N2 - Rett syndrome (RTT) is an X-linked neurodevelopmental disorder linked to heterozygous de novo mutations in the MECP2 gene. MECP2 encodes methyl-CpG-binding protein 2 (MeCP2), which represses gene transcription by binding to 5-methylcytosine residues in symmetrically positioned CpG dinucleotides. Direct MeCP2 targets underlying RTT pathogenesis remain largely unknown. Here, we report that FXYD1, which encodes a transmembrane modulator of Na+,K+-ATPase activity, is elevated in frontal cortex (FC) neurons of RTT patients and Mecp2-null mice. Increasing neuronal FXDY1 expression is sufficient to reduce dendritic arborization and spine formation, hallmarks of RTT neuropathology. Mecp2-null mouse cortical neurons have diminished Na+,K+-ATPase activity, suggesting that aberrant FXYD1 expression contributes to abnormal neuronal activity in RTT. MeCP2 represses Fxyd1 transcription through direct interactions with sequences in the Fxyd1 promoter that are methylated in FC neurons. FXYD1 is therefore a MeCP2 target gene whose de-repression may directly contribute to RTT neuronal pathogenesis.

AB - Rett syndrome (RTT) is an X-linked neurodevelopmental disorder linked to heterozygous de novo mutations in the MECP2 gene. MECP2 encodes methyl-CpG-binding protein 2 (MeCP2), which represses gene transcription by binding to 5-methylcytosine residues in symmetrically positioned CpG dinucleotides. Direct MeCP2 targets underlying RTT pathogenesis remain largely unknown. Here, we report that FXYD1, which encodes a transmembrane modulator of Na+,K+-ATPase activity, is elevated in frontal cortex (FC) neurons of RTT patients and Mecp2-null mice. Increasing neuronal FXDY1 expression is sufficient to reduce dendritic arborization and spine formation, hallmarks of RTT neuropathology. Mecp2-null mouse cortical neurons have diminished Na+,K+-ATPase activity, suggesting that aberrant FXYD1 expression contributes to abnormal neuronal activity in RTT. MeCP2 represses Fxyd1 transcription through direct interactions with sequences in the Fxyd1 promoter that are methylated in FC neurons. FXYD1 is therefore a MeCP2 target gene whose de-repression may directly contribute to RTT neuronal pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=34247170462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247170462&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddm007

DO - 10.1093/hmg/ddm007

M3 - Article

C2 - 17309881

AN - SCOPUS:34247170462

VL - 16

SP - 640

EP - 650

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 6

ER -